Post Reply
221-240 of 409
Currently $0.320.
Results coming out. Expecting it to be better than prior.
Good company and with solid FA.
Good bet today if results this week end , can expect a gap up next Monday.
DYODD and I reckon today entry would be a value bet indeed.
Break out in the making this one
Results coming out. Expecting it to be better than prior.
Good company and with solid FA.
Good bet today if results this week end , can expect a gap up next Monday.
DYODD and I reckon today entry would be a value bet indeed.
Break out in the making this one
david_12 ( Date: 13-Feb-2022 20:13) Posted:
|
On an upward trend.
should be 19 Feb (https://sginvestors.io/sgx/stock/5ot-singmedical/company-announcement)
When is next result announcement?
ya, spotted the movements.
I m Queuing at 30 cents, hope to get it
tccroy ( Date: 08-Feb-2022 09:33) Posted:
|
Seems like volume going up pretty soon with improved performance
There is some volume recently, good news coming?
It seems waking up very soon...keep a look out..
I think this one will fly soon. Accumulation at 31.5...
Singapore Medical Group to acquire 50% stake in Vietnam JV for S$3.04m
SINGAPORE Medical Group (SMG) has proposed to acquire the 50 per cent stake it does not own in its joint-venture company, SMG International Vietnam (SMG IV), for S$3.04 million as part of plans to expand in Vietnam amid rising private healthcare demand.
SMG IV was incorporated in December 2016 to explore and invest in potential growth and acquisition opportunities.
Following the proposed acquisition, SMG will in turn effectively own a 42 per cent stake in CityClinic Asia Investments (CCAI), which operates three medical centres in Ho Chi Minh City, said the group in a bourse filing on Thursday.
CCAI' s wholly-owned subsidiary, CityClinic Vietnam Limited, holds a 100 per cent foreign-investor licence for Vietnamese healthcare operations and runs the CarePlus Vietnam brand of medical centres.
SMG said the CarePlus footprint spans strategically across Ho Chi Minh City, including two 15,000 square feet (sq ft) centres in the Tan Binh District and District 7. More recently, it opened its third site, which covers 10,000 sq ft in Ho Chi Minh City' s prime District 1.
These centres provide multi-disciplinary healthcare specialists services, which focus on health screening, women' s health, paediatrics and diagnostic imaging, among others.
Vietnam remains one of the fastest growing economies in South-east Asia, with real gross domestic product growth expected to average at 6.1 per cent annually from 2019 to 2025.
Amid this rapidly advancing economy, a large pool of expatriates, alarming rates of cancer and a total fertility rate of 2.0 - among the highest in Asia and almost double that of Singapore' s - Vietnam presents a unique opportunity for SMG' s next phase of overseas growth, it said.
Beng Teck Liang, chief executive officer of SMG, said: " Our latest investment will ensure that we are well-positioned to expand our operations in core competencies such as women' s health, paediatrics, oncology and other specialist verticals.
Now I know why it is being tied down to 0.315 to 0.32 range...it makes sense now. Keep some, rocket soon..
desmondxyz ( Date: 05-Aug-2021 13:56) Posted:
|
RMG up gao gao....why SMG so soft....
Yes. Accumulation in process, target 0.4x.
Invest1 ( Date: 04-Aug-2021 09:43) Posted:
|
PROJECT SUPER II....
There is an accumulation going on. There should be an out break soon.
Singapore Medical Group H1 earnings more than double on demand in diagnostics, aesthetics
THE H1 net profit of Singapore Medical Group $ SingMedical: 5OT +1.54% (SMG) more than doubled to S$7.2 million for the half-year period ended June 30, up from S$3.5 million a year ago due to rising demand in the group' s aesthetics, Lasik and diagnostic imaging-related services.
The Catalist-listed group said its half-yearly profit was 5.1 per cent higher compared to pre-Covid-19 levels in H1 FY2019.
SMG&rsquo s executive director and chief executive officer Beng Teck Liang said that the results came as &ldquo a bit of a surprise&rdquo and attributed the increased demand for procedures such as health check-ups, plastic surgery and Lasik by Singaporeans, who have been unable to leave for other countries like Malaysia and Korea to complete these treatments.
&ldquo Consumers have discovered that, actually, Singapore is very good at these services,&rdquo he said, adding that medical consumers tend to develop a &ldquo strong stickiness&rdquo to these services and will return to the group for treatments.
In its financial results released on Tuesday, the Catalist-listed group posted earnings per share of 1.49 Singapore cents over the same period, up 106.9 per cent from 0.72 cent the year before.
Revenue for the half-year rose to S$49.7 million, up 27.6 per cent from the S$38.9 million a year ago. Notably, revenue is also 11.3 per cent higher than the S$44.6 million the group generated pre-Covid-19 in the first half of FY2019.
SMG attributed this to the S$19.8 million in revenue generated within its diagnostic and aesthetics segment, representing a surge of 76.5 per cent year-on-year.
The group' s performance in the health segment was also resilient, with revenue growing by 8.7 per cent from a year ago to S$30.5 million despite the severe curb of medical tourism, which used to account for 15 to 20 per cent of revenue.
Dr Beng expressed optimism that as travel restarts, medical tourism will recover as Singapore&rsquo s reputation as a trusted destination for more complex medical cases remains strong.
&ldquo It may not immediately recover to the way it used to be, but it will certainly start to trickle back and gain momentum as travel returns,&rdquo he said.
The return of medical tourism, coupled with pent-up local demand for services because of the recent Phase 2 (Heightened Alert) measures, give him hope that the second-half of the year will be &ldquo incredible&rdquo .
As at June 30, the group said that its net cash position also improved to S$18.1 million, from SS$15.8 million as at Dec 31, 2020 while its gearing improved to 4.1 per cent, from 6.4 per cent before.
No dividend has been declared or recommended for the half-year period, unchanged from a year ago.
In pursuit of organic growth, SMG said that it will look to strengthen its position within the women' s and children' s space by hiring new specialists in obstetrics and gynaecology (O& G) and paediatricians in addition to opening new clinics.
As for the group' s overseas investments, SMG expects business conditions to remain challenging in the near term for two of the group' s overseas entities, CityClinic Asia investments in Vietnam and PT Ciputra SMG in Indonesia, due to the pandemic.
Still, the group has sought to adapt to the pandemic with CarePlus Vietnam, its chain of specialist and primary-care clinics, seeing good traction after pivoting towards Covid-19 testing, said Dr Beng.
Furthermore, the group noted that City Fertility, its Australian partner and one of Australia' s largest in-vitro fertilisation and fertility service groups, is in the final stages of closing an earnings accretive acquisition that will help it enter the Western Australian market, where it currently has no presence.
Fantastic results...
The only sensible thing to do is to hold on to his baby and not time the market.
The only sensible thing to do is to hold on to his baby and not time the market.
No wonder the last takeover cannot go thru. If the business is good and profit is double, I will also want to sell my company much higher...
Maybe we can wait for a new takeover offer soon.
Maybe we can wait for a new takeover offer soon.
Singapore Medical Group H1 earnings more than double on demand in diagnostics, aesthetics
Singapore Medical Group' s H1 net profit more than doubled to S$7.2 million for the half-year period ended June 30, 2021, up from S$3.5 million a year ago due to rising demand in the group' s aesthetics, Lasik and diagnostic imaging-related services.The Catalist-listed group said its half-yearly profit was 5.1 per cent higher compared to pre-Covid-19 levels in H1 FY2019.
In its financial results released on Tuesday, the Catalist-listed group posted earnings per share of 1.49 Singapore cents over the same period, up 106.9 per cent from 0.72 cent the year before.
Revenue for the half-year rose to S$49.7 million, up 27.6 per cent from the S$38.9 million a year ago. Notably, revenue is also 11.3 per cent higher than the S$44.6 million the group generated pre-Covid-19 in the first half of FY2019.
SMG attributed this to the S$19.8 million in revenue generated within its diagnostic and aesthetics segment, representing a surge of 76.5 per cent year-on-year.
The group' s performance in the health segment was also resilient, with revenue growing by 8.7 per cent from a year ago to S$30.5 million despite the severe curb of medical tourism, which used to account for 15 to 20 per cent of revenue.
As at June 30, the group said that its net cash position also improved to S$18.1 million, from SS$15.8 million as at Dec 31, 2020 while its gearing also improved to 4.1 per cent, from 6.4 per cent before.
SMG' s executive director and chief executive officer Beng Tech Liang said: " Backed by our strengthened balance sheet, this is just the beginning as we are looking to emerge stronger from the pandemic via both organic and inorganic growth strategies."
No dividend has been declared or recommended for the half-year period.
Shares of SMG closed flat at 32.5 Singapore cents on Monday.